ArticleScientific reports2026
Mitochondria-targeting ACSL6 variant drives mitochondrial fragmentation potentially through local DHA-CoA production.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ALDH1B1 promotes mitochondrial γ-butyrobetaine biosynthesis and fatty acid oxidation in colorectal cancer.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Fatty acids are metabolized into fatty acid-coenzyme A (CoA) by the acyl-CoA synthetase (ACS). Acsl6 is an ACS that preferentially uses polyunsaturated fatty acids such as docosahexaenoic acid (DHA) as substrates. Acsl6 is essential for maintaining normal brain function, visual function, and male fertility. The enzymatic activities of Acsl6 isoforms harboring distinct fatty acid gate-domain motifs differ. However, no studies have comprehensively analyzed the differences in the expression profiles of Acsl6 variants in various tissues. We determined the relative expression levels of the Acsl6 variants in tissues and identified Acsl6-short as the dominant isoform expressed in the brain, retina, and testes. The Acsl6-short is exclusively localized to the mitochondria when transiently expressed in HeLa cells. DHA treatment dynamin-related protein 1 (Drp1)/Mid49/Mid51-dependently induced mitochondrial fragmentation in Acsl6-short-overexpressing HeLa cells. These results suggested that the mitochondrial fragmentation was induced via the local production of DHA-CoA by the Acsl6-short expressed in the mitochondria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.